首页> 美国卫生研究院文献>Clinical Molecular Pathology >Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue
【2h】

Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue

机译:细胞角蛋白20 RT-PCR检测大肠癌患者血液和骨髓中弥散性肿瘤细胞的局限性:在对照组织中的表达和在肿瘤组织中的下调

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Aims: Despite informative staging of patients with colorectal cancer, some patients with localised disease at diagnosis will develop recurrence or metastasis. Attempts to improve staging include sensitive detection of disseminated tumour cells in blood and bone marrow by reverse transcriptase polymerase chain reaction (RT-PCR). The results of this study have been considered in relation to the controversial results in the literature to elucidate the usefulness of cytokeratin 20 (CK20) RT-PCR to detect disseminated tumour cells further.>Patients/Methods: Blood and bone marrow samples from 30 patients with colorectal cancer were studied by CK20 RT-PCR. Specificity was evaluated in 47 blood and 15 bone marrow samples from non-cancer controls. In addition, the expression of CK20 mRNA and protein was studied in normal and tumour colon tissue samples.>Results: CK20 expression was detected in nine of 30 and nine of 19 of the blood and bone marrow samples from patients with colorectal cancer, respectively. In non-cancer control blood and bone marrow samples, CK20 expression was detected in 10 of 47 and four of 15, respectively. A difference between patient and control samples may be observed in terms of frequency of positive PCR tests. In tissue samples, CK20 mRNA expression was downregulated in tumour compared with normal colon tissue.>Conclusions: CK20 expression was downregulated in tumour tissue compared with normal colon and a background expression of CK20 was seen in some control blood and bone marrow samples. Despite a lack of standardisation (which hampers comparison of studies), these results, together with other reports in the literature, suggest that CK20 may still be a suitable marker, but that background expression and threshold setting should be studied further.
机译:>目标:尽管对结直肠癌患者进行了有意义的分期,但某些在诊断时患有局部疾病的患者仍会复发或转移。改善分期的尝试包括通过逆转录酶聚合酶链反应(RT-PCR)敏感地检测血液和骨髓中已扩散的肿瘤细胞。这项研究的结果已与文献中有争议的结果联系起来,以阐明细胞角蛋白20(CK20)RT-PCR在进一步检测已扩散的肿瘤细胞中的作用。>患者/方法:通过CK20 RT-PCR研究了30例大肠癌患者的骨髓样本。在来自非癌症对照的47个血液和15个骨髓样品中评估了特异性。此外,还研究了正常和肿瘤结肠组织样本中CK20 mRNA和蛋白的表达。>结果:在来自患者的血液和骨髓样本中每30个样本中有9个和19个样本中有9个检测到了CK20表达分别与大肠癌。在非癌症对照血液和骨髓样本中,分别在47个中的10个和15个中的四个中检测到CK20表达。就阳性PCR测试的频率而言,可以观察到患者和对照样品之间的差异。在组织样本中,与正常结肠组织相比,肿瘤中CK20 mRNA表达下调。>结论:与正常结肠相比,肿瘤组织中CK20表达下调,并且在一些对照血液和组织中,CK20的背景表达骨髓样本。尽管缺乏标准化(妨碍进行研究比较),但这些结果以及文献中的其他报道表明,CK20仍可能是合适的标记物,但应进一步研究背景表达和阈值设置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号